Swiss Re’s Bristol-Myers Squibb BMY Stock Holding History

Swiss Re’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$28.5K	Hold	470	–	–	0.17%	81
2025 Q4	$25.4K	Buy	+470	New	+$22.6K	﹤0.01%	96

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Swiss Re's BMY Position: Q1 2026 in Review

Swiss Re held its Bristol-Myers Squibb (BMY) position steady in Q1 2026 at 470 shares worth $28.5K. The position accounts for 0.17% of the portfolio, ranked #81.

Swiss Re first reported a position in BMY in Q4 2025 and has held it in 2 quarters since. 2,521 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

Swiss Re held 470 shares of Bristol-Myers Squibb worth $28.5K as of Q1 2026.
Swiss Re left its Bristol-Myers Squibb share count unchanged in Q1 2026.
Bristol-Myers Squibb made up 0.17% of Swiss Re's portfolio in Q1 2026, its #81 holding.
Swiss Re first reported a position in Bristol-Myers Squibb in Q4 2025 and has held it in 2 quarters since.
2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Swiss Re's 13F filing for Q1 2026, filed 12 May 2026.